CIC
CORT icon

Cornercap Investment Counsel’s Corcept Therapeutics CORT Stock Holding History

Cornercap Investment Counsel’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9,212
Closed -$464K – 218
2024
Q4 		$464K Hold
9,212
– – 0.15% 233
2024
Q3 		$426K Sell
9,212
-13,785
-60% -$490K 0.13% 288
2024
Q2 		$747K Sell
22,997
-245
-1% -$6.71K 0.12% 305
2024
Q1 		$585K Buy
23,242
+3,986
+21% +$94.2K 0.09% 368
2023
Q4 		$625K Buy
+19,256
New +$529K 0.1% 352
2018
Q3 		– Sell
-44,555
Closed -$700K – 407
2018
Q2 		$700K Buy
+44,555
New +$775K 0.1% 328

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Cornercap Investment Counsel's CORT Position: Q1 2025 in Review

Cornercap Investment Counsel sold out of Corcept Therapeutics (CORT) in Q1 2025, closing a stake of 9,212 shares — an estimated $464K sold.

Cornercap Investment Counsel first reported a position in CORT in Q2 2018 and held it in 6 quarters. The position peaked at $747K in Q2 2024. 422 funds tracked by Wall St. Rank hold CORT as of Q1 2025.

  • Cornercap Investment Counsel reported no remaining Corcept Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Cornercap Investment Counsel sold 9,212 Corcept Therapeutics shares in Q1 2025, an estimated $464K.
  • Cornercap Investment Counsel first reported a position in Corcept Therapeutics in Q2 2018 and held it in 6 quarters.
  • Cornercap Investment Counsel's Corcept Therapeutics position peaked at $747K in Q2 2024.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2025.

Based on Cornercap Investment Counsel's 13F filing for Q1 2025, filed 2 May 2025.